Choose Your Country or Region

Roflumilast (B9302-107)

Name: Roflumilast (B9302-107)
Brand: Selleck Chemicals
SKU: S2131
Rating: 5 (18 reviews)

Catalog No.S2131 Synonyms: APTA 2217, BY 217, BYK 20869

For research use only.

Roflumilast (APTA 2217, B9302-107, BY 217, BYK 20869) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.

Roflumilast (B9302-107) Chemical Structure

CAS No. 162401-32-3

Selleck's Roflumilast (B9302-107) has been cited by 18 publications

Purity & Quality Control

Choose Selective PDE Inhibitors

Related Compound Libraries

Other PDE Products

U73122^New

U73122 is a potent phospholipase C (PLC) inhibitor, which reduces agonist-induced Ca²⁺ increases in platelets and PMN. U73122 potently inhibits human 5-lipoxygenase (5-LO).
Liproxstatin-1^New

Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM.
Epacadostat (INCB024360)^New

Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).
Sildenafil Citrate

Sildenafil Citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.
Rolipram (ZK-62711)

The PDE4 selective inhibitor, Rolipram (ZK-62711, SB 95952), inhibited immunopurified PDE4B and PDE4D activities similarly, with IC50 values of approx. 130 nM and 240 nM respectively; an anti-inflammatory agent.
Tadalafil (IC351)

Tadalafil (IC351) is a PDE-5 inhibitor with IC50 of 1.8 nM in a cell-free assay. Tadalafil is at least 9000 times more selective for PDE5 than most of the other families of PDEs, with the exception of PDE11. It can partial inhibits PDE11
Mardepodect (PF-2545920)

Mardepodect (PF-2545920) is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE.
Apremilast (CC-10004)

Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.
Luteolin

Luteolin (Luteoline, Luteolol, Digitoflavone) is a flavonoid found in Terminalia chebula, which is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively. Phase 2.
Deltarasin

Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with K_d of 38 nM for binding to purified PDEδ.

Download Inhibitor Catalog

PDE Signaling Pathway Map

Biological Activity

Description

Roflumilast (APTA 2217, B9302-107, BY 217, BYK 20869) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay.

Targets

PDE4B2 ^[1] (Cell-free assay)	PDE4A1 ^[1] (Cell-free assay)	PDE4B1 ^[1] (Cell-free assay)	PDE4A4 ^[1] (Cell-free assay)	PDE4C1 ^[1] (Cell-free assay)	Click to View More Targets
0.2 nM	0.7 nM	0.7 nM	0.9 nM	3 nM	Click to View More Targets

In vitro

Roflumilast displays anti-inflammatory and immunomodulatory in vitro. Roflumilast inhibits LTB4 synthesis in human neutrophil with IC50 of 2 nM. Roflumilast inhibits fMLP-stimulated ROS formation as luminol-enhanced CL in human neutrophils or eosinophils with IC35 of 4 nM, and 7 nM, repectively. Roflumilast inhibits LPS-stimulated TNF-α synthesis in monocytes with IC40 of 21 nM. Roflumilast inhibits TNF-α synthesis in monocyte-derived dendritic cells with IC20 of 5 nM. Rolfumilast inhibits anti-CD3 and anti-CD28 antibody-stimulated proliferation of CD4+ T cells with IC30 of 7 nM. Rolfumilast inhibits anti-CD3 and anti-CD28 antibody-stimulated synthesis of IL-2, IL-4, IL-5, and IFN-v in CD4+ T cells with IC20 of 1 nM, IC30 of 7 nM, IC25 of 13 nM, and IC35 of 8 nM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

PBMC	NIrncW1HfW6ldHnvckBie3OjeR?=		M{mxXGlvcGmkaYTpc44hd2ZiVF7GZYxxcGFicILv[JVkfGmxbjDpckBNWFNvc4TpcZVt[XSnZDDoeY1idiCSQl3DJJBz\WmwY4XiZZRm\CCkZX\vdoUhVFCVIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCnbor5cYUhcW2vdX7vZZN{[XluIFnDOVA:OmVvMEWg{txO	M1jFcFE6OjV4NUC3
sf21 cells	MlHXSpVv[3Srb36gZZN{[Xl?		NET1PZJKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHygcIVv\3SqIGDESVRCPCCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z{MTDj[YxteyxiSVO1NF0xNjN3IH7N	MnzINlM5ODZ3NUO=
HEK293 cells	MVzGeY5kfGmxbjDhd5NigQ>?	Mm\YNVUhdWmw	M1HYNGlvcGmkaYTpc44hd2ZiUFTFOEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINw\XiycnXzd4lv\yCleXPsbYMhdnWlbHXveIll\SCpYYTl[EBqd25iY3jhco5mdCCvdYThcpQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBPTUODLXnu[JVk\WRiY1HNVEBxem:mdXP0bY9vKHS{ZXH0[YQhOTVibXnud{Bj\W[xcnWgUmVESSClaHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhPDVibXnud{BjgSCITFnQVkBie3OjeR?=	NVHEeJpSOjB\|N{izOFg>

Click to View More Cell Line Experimental Data

In vivo

Roflumilast is activity against pulmonary inflammatory response related to COPD in animal model. Roflumilast (5 mg/kg/day) induces reduction of neutrophils, macrophages, DC, B-cells, CD4⁺ T cells, CD8⁺ T cells in the lung of mice exposed to tobacco smoke for 7 month by 78%, 82%, 48%, 100%, 98%, and 88%, respectively. ^[3] Roflumilast is an efficient inhibitor of lung fibrotic remodeling. Roflumilast dose-dependently diminishes total lung hydroxyproline after bleomycin, attaining about 47% inhibition at 5 mg/kg/day, paralleled by a reduction in lung αI(I) collagen transcripts and fibrotic lesions. Roflumilast reduces oxidative stress in vivo. Roflumilast (5 mg/kg/day) moderately reduces an increase in BAL fluid lipid hydroperoxides measured at day 14 after intratracheal bleomycin administration in mice. ^[4]

Protocol (from reference)

References

[4] Cortijo J, et al. Br J Pharmacol, 2009, 156(3), 534-544.

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing. Click to purchase: PEG400 Tween 80	30 mg/mL

Chemical Information

Molecular Weight	403.21
Formula	C₁₇H₁₄Cl₂F₂N₂O₃
CAS No.	162401-32-3
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F

Download Roflumilast (B9302-107) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04279119	Completed	Drug: ARQ-151- cream 0.3%	Plaque Psoriasis	Arcutis Biotherapeutics Inc.	March 10 2020	Phase 1
NCT04156191	Recruiting	Drug: ARQ-151 cream 0.15%\|Drug: ARQ-151 cream 0.05%	Atopic Dermatitis (Eczema)	Arcutis Biotherapeutics Inc.	December 23 2019	Phase 1
NCT03762330	Unknown status	Behavioral: COPD structured self-management plan.	Chronic Obstructive Pulmonary Disease	Jordi Gol i Gurina Foundation\|Institut Catala de Salut	January 19 2019	Not Applicable
NCT01862029	Completed	Drug: Roflumilast	Obesity	National Heart Lung and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	May 22 2013	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Could you tell me which diluent you advise to use with S2131 for in vivo applications in mice?

Answer:
For s2131, the in vivo formulation is 30% PEG400+0.5% Tween80+5% Propylene glycol up to 30mg/mL.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):